Abstract
We report the results of the biochemical evaluation of a series of imidazole-based compounds against the hydroxysteroid dehydrogenase (HSD) family of enzymes, in particular, types 1 and 3 of 17β-HSD and 3β-HSD. The results show that the synthesised compounds were good inhibitors of this family of enzymes.
Keywords: Enzyme, Inhibition, Azole, Hydroxysteroid dehydrogenase, 17α-hydroxylase, 17,20-lyase
Letters in Drug Design & Discovery
Title: Inhibition of 17β -Hydroxysteroid Dehydrogenase (17β -HSD) by Imidazole-Based Compounds
Volume: 5 Issue: 1
Author(s): Sabbir Ahmed, Moniola S. Olusanjo, Imran Shahid and Caroline P. Owen
Affiliation:
Keywords: Enzyme, Inhibition, Azole, Hydroxysteroid dehydrogenase, 17α-hydroxylase, 17,20-lyase
Abstract: We report the results of the biochemical evaluation of a series of imidazole-based compounds against the hydroxysteroid dehydrogenase (HSD) family of enzymes, in particular, types 1 and 3 of 17β-HSD and 3β-HSD. The results show that the synthesised compounds were good inhibitors of this family of enzymes.
Export Options
About this article
Cite this article as:
Ahmed Sabbir, Olusanjo S. Moniola, Shahid Imran and Owen P. Caroline, Inhibition of 17β -Hydroxysteroid Dehydrogenase (17β -HSD) by Imidazole-Based Compounds, Letters in Drug Design & Discovery 2008; 5 (1) . https://dx.doi.org/10.2174/157018008783406705
DOI https://dx.doi.org/10.2174/157018008783406705 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes
Letters in Drug Design & Discovery Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations
Current Topics in Medicinal Chemistry Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Current Drug Targets Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK
Current Cancer Drug Targets Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Meet Our Editorial Board Member:
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Bacteriochlorins and Their Potential Utility in Photodynamic Therapy (PDT)
Current Organic Chemistry Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Synthesis of Novel 1,4-Substituted 1,2,3-Triazoles by Water-Soluble (Salicyladimine) <sub>2</sub>Cu Complex Catalyzed Azide-Alkyne Cycloaddition in Water
Letters in Organic Chemistry Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry